BioCatalyst

EIKN — Eikon Therapeutics, Inc. catalysts

1 verified catalyst event(s) for Eikon Therapeutics, Inc. (ticker EIKN). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-12-01 — A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With S · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patie
Phase 2 · NSCLC
 EIKN Eikon Therapeutics, Inc. EIK1001, Pembrolizumab, Paclitaxel, Peme ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.